1450 related articles for article (PubMed ID: 36044198)
1. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
2. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
3. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
Livingston NA; Sarpong A; Sistad R; Roth C; Banducci AN; Simpson T; Hyde J; Davenport M; Weisberg R
J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
[TBL] [Abstract][Full Text] [Related]
4. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
6. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
7. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
[TBL] [Abstract][Full Text] [Related]
8. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
[TBL] [Abstract][Full Text] [Related]
9. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
10. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
Hailu R; Mehrotra A; Huskamp HA; Busch AB; Barnett ML
JAMA Netw Open; 2023 Jan; 6(1):e2252381. PubMed ID: 36692880
[TBL] [Abstract][Full Text] [Related]
11. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
12. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
13. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
14. Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers.
Sung ML; Black AC; Blevins D; Henry BF; Cates-Wessel K; Dawes MA; Drexler K; Hagle H; Molfenter T; Levin FR; Becker WC; Edelman EJ
J Addict Med; 2022 Sep-Oct 01; 16(5):505-513. PubMed ID: 35020698
[TBL] [Abstract][Full Text] [Related]
15. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
17. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
[TBL] [Abstract][Full Text] [Related]
18. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
[No Abstract] [Full Text] [Related]
19. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
20. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K; Hills H; Ma J; Brown CH; McGovern M
Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
